爾康製藥(300267.SZ):孫公司擬9450萬元投建間苯二酚等產品項目
格隆匯 10 月 12日丨爾康製藥(300267.SZ)公佈,2020年10月12日,公司第四屆董事會第十次會議審議通過《關於全資孫公司投資建設間苯二酚等產品項目的議案》。為進一步完善公司產品結構、深化落實戰略佈局,同意公司全資孫公司鳳凰實業有限公司(“鳳凰實業”)以自籌資金9450萬元投資建設間苯二酚等產品項目,項目建設期為1年,項目建設地點為柬埔寨王國馬德望省。
該項目主要建設內容為相關生產車間及配套設施,生產包括間苯二酚、磺胺甲噁唑等產品。項目主要產品情況:
1、間苯二酚具有殺菌作用,可用作防腐劑,醫藥上外用治濕疹、牛皮癬等皮膚病,添加於皮膚病藥物糊劑、軟膏或化粧品中。在其他領域,間苯二酚主要用於橡膠粘合劑、合成樹脂、染料和分析試劑等,也可以用作多種有機藥品和染料製造的中間體。
2、磺胺甲噁唑是合成磺胺類抗菌藥,屬全身應用的中效磺胺類藥物,它可與PABA競爭性作用於細菌體內的二氫葉酸合成酶,阻止細菌二氫葉酸的合成,從而抑制細菌的生長繁殖。磺胺甲噁唑與磺胺嘧啶、磺胺異惡唑、三磺嘧啶三種磺胺類藥物是目前治療諾卡菌病(一種人畜共患傳染病,可見於晚期艾滋病患者機會性感染)較好藥物。主要用於敏感菌引起的尿路感染、呼吸系統感染、腸道感染、膽道感染及局部軟組織或創面感染等。
近年來國內供給側改革進入深水區,環保政策持續收緊,原輔料產業結構不斷調整。公司緊跟“一帶一路”政策號召,在前期已進行戰略佈局,將原輔料產業鏈前移、外移。公司投資建設該項目,順應發展形勢的同時,有利於公司進一步深化落實戰略佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.